HHS officials earlier this week announced that health insurance premiums under the Affordable Care Act plans will, on the average, increase by 25 percent next year.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
